Evidence map›Paper›PMID 36116273›Full record

ArticleComparative immunology, microbiology and infectious diseases2022

Surveillance for multidrug resistant Escherichia coli carriage in cattle, dogs and humans reveals predominance of CMY-2, CTX-M-15 and CTX-M-9 groups of β-lactamases.

Daniel A Ortiz, Laurel M Legenza, Brooke J Olson, Cindy C Knapp, Scott B Killian, Jennifer K Meece, Matthew C Hall, Thomas R Fritsche

Open access · greenAbstract read
In one paragraph

Article in Comparative immunology, microbiology and infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Daniel A OrtizBeaumont Health, Royal Oak, MI 48073, USA.
Laurel M LegenzaUniversity of Wisconsin, Madison, WI 53706, USA.
Brooke J OlsonMarshfield Clinic Health System, Marshfield, WI 54449, USA.
Cindy C KnappThermo Fisher Scientific, Oakwood Village, OH 44146, USA.
Scott B KillianThermo Fisher Scientific, Oakwood Village, OH 44146, USA.
Jennifer K MeeceMarshfield Clinic Health System, Marshfield, WI 54449, USA.
Matthew C HallMarshfield Clinic Health System, Marshfield, WI 54449, USA.
Thomas R FritscheMarshfield Clinic Health System, Marshfield, WI 54449, USA. Electronic address: fritsche.thomas@marshfieldclinic.org.
Marshfield Clinic · USThermo Fisher Scientific (United States) · USBeaumont Health · USUniversity of Wisconsin–Madison · US

Funding

University of Wisconsin Institute for Clinical and Translational ResearchUL1TR002373 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI ELIZABETH S BURNSIDE, Allan R. Brasier · 2017 to 2026
$75.9M
NCATS NIH HHS UL1 TR002373
6 · The paper itself

Abstract

Global spread of antimicrobial multidrug resistance (MDR) in human and veterinary medicine relies upon diagnostics, surveillance and stewardship to guide mitigation. Utilizing surveillance of fecal samples from our service area for detecting MDR Escherichia coli carriage in humans (2143), dogs (627), and cattle (130), we found isolates resistant to third/fourth generation cephems present in 3.7 %, 13.1 %, and 51.5 %, respectively. CMY-2, CTX-M-15-like and CTX-M9 group genes in descending order were predominant in all hosts and accounted for 83.3 % of non-wild-type gene targets. MDR carriage mirrored cephem non-susceptibility rates as published in annual antibiograms for humans and dogs; notably, no carbapenem-resistant carriage isolates were detected. Given the scale of MDR E. coli carriage in cattle (14X) and dogs (3.5X) compared to humans, bench-marking of the resistance gene pool by host species utilizing regional One Health surveillance may aid in assessing occupational and geographic risks for acquiring resistance and for monitoring of mitigation strategies.

Indexed as

Anti-Infective AgentsCattle DiseasesDog DiseasesEscherichia coli InfectionsAnimalsAnti-Bacterial Agentsbeta-LactamasesCattleDogsEscherichia coliHumansMicrobial Sensitivity TestsAnti-Bacterial AgentsAnti-Infective Agentsbeta-LactamasesAmpCCREDNA microarrayE. coli, ESBLOne HealthSurveillance

Identifiers

PMID36116273
PMCPMC11917207
OpenAlexW4296123378

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.